PD Dr. Matthias Moll, MBA

Medizinstudium, Universität Tübingen, Deutschland

MBA, WU Vienna

LLM, WU Vienna

Habilitation, Medizinische Universität Wien

Facharztausbildung, AKH Wien

Junior Berater, BCG

Facharzt für Radioonkologie, MedAustron

Mitglied der ÖGRO

Biochemical control in intermediate- and high-risk prostate cancer after EBRT with and without brachytherapy boost
doi: 10.1007/s00066-024-02245-3.

Radiotherapy in localized prostate cancer: a multicenter analysis evaluating tumor control and late toxicity after brachytherapy and external beam radiotherapy in 1293 patients
doi: 10.1007/s00066-024-02222-w.

The role of artificial intelligence in informed patient consent for radiotherapy treatments-a case report
doi: 10.1007/s00066-023-02190-7.

Assessing the toxicity after moderately hypofractionated prostate and whole pelvis radiotherapy compared to conventional fractionation
doi: 10.1007/s00066-023-02104-7.

Effects of gold fiducial marker implantation on tumor control and toxicity in external beam radiotherapy of prostate cancer
doi: 10.2478/raon-2023-0004.

Advancements in the radiooncological treatment of high-risk prostate cancer: a quarter century of achievements
doi: 10.2478/raon-2022-0018.

Clinical outcome in metastatic prostate cancer after primary radiotherapy
doi: 10.1007/s00066-022-01993-4.

Comparative effectiveness of moderate hypofractionation with volumetric modulated arc therapy versus conventional 3D-radiotherapy after radical prostatectomy
doi: 10.1007/s00066-022-01909-2.

Comparison of EBRT and I-125 seed brachytherapy concerning outcome in intermediate-risk prostate cancer
doi: 10.1007/s00066-021-01815-z.

Treatment of low-risk prostate cancer: a retrospective study with 477 patients comparing external beam radiotherapy and I-125 seeds brachytherapy in terms of biochemical control and late side effects
doi: 10.1007/s00066-020-01657-1.